HOME >> BIOLOGY >> NEWS
Researchers identify potential therapeutic target for Huntington's disease

Researchers studying yeast cells have identified a metabolic enzyme as a potential therapeutic target for treating Huntington's disease, a fatal inherited neurodegenerative disorder for which there is currently no effective treatment. The group, whose results appear in the May issue of Nature Genetics, includes researchers from the University of Washington School of Medicine in Seattle and the University of Maryland School of Medicine in Baltimore. The paper was published online in advance at the journal's Web site, http://www.nature.com/ng/index.html.

The group performed a genetic experiment known as a loss-of-function suppressor screen, which searches for genes that, when switched off, reduce the toxic effects of the mutant protein associated with Huntington's. One of the genes they identified encodes an enzyme, called KMO, that has been previously implicated in the disease. The enzyme functions in a metabolic pathway that is activated at early stages of the disease in people with Huntington's, as well as in animal models of the disease.

"The nice thing about this finding is that there is a chemical compound available that inhibits KMO activity," said Dr. Paul Muchowski, assistant professor of pharmacology at the UW, who led the study. "We're in the midst of testing that compound in a mouse model of Huntington's disease."

Further support for KMO as a therapeutic target for Huntington's disease comes from a recent study led by Dr. Aleksey G. Kazantsev of Harvard Medical School. In this study, researchers used cell-based experiments to screen about 20,000 chemical compounds, and identified one that suppresses neurodegeneration in a fly model of the disease. That compound has a very similar chemical structure as the drug that inhibits the target identified by Muchowski's group. The results appeared in the Jan. 18, 2005, issue of the Proceedings of the National Academy of Sciences.

In ad
'"/>

Contact: Justin Reedy
jreedy@u.washington.edu
206-685-0382
University of Washington
6-Apr-2005


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... YORK (PRWEB) , ... September 03, 2020 , ... ... real world data, today announced that an extensive third-party assessment of the company’s ... and compliant when measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ ...
(Date:8/23/2020)... ... August 21, 2020 , ... The August edition of ... is now available on the company’s global website. Crystallography Times—an electronic newsletter published ... current news and crystallographic research. , The latest issue of Crystallography Times ...
(Date:8/12/2020)... ... 11, 2020 , ... Both Roche, based in Basel, Switzerland, ... agreements with Housey Pharma’s HMI subsidiary to gain access to its core-enabling technology ... and Development spending in excess of US $10 billion. , Scientists at Housey ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading platform for ... Board (SAB) to research the medical potential of terpenes and the potential entourage ... terpenes. The board is focused on expanding the recently launched line of effects-based terpenes ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... cold chain validation engineering firm, is making available for free its new ... to incorporate concurrent transport simulation testing into today’s biologics licensing application (BLA). ...
(Date:8/3/2020)... ... , ... ERT, the global leader in clinical ... one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice. ... on how they have inspired their colleagues and affected positive changes in their ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... announced the launch of its new tagline, “BUILDING FOR LIFE.” The adoption of ... and around the globe, requiring fast track capacity to provide patients with urgently ...
Breaking Biology Technology:
Cached News: